Invesco Biotechnology & Genome ETF
PBE
87 hedge funds and large institutions have $165M invested in Invesco Biotechnology & Genome ETF in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
28% more capital invested
Capital invested by funds: $129M → $165M (+$36M)
6% more funds holding
Funds holding: 82 → 87 (+5)
2.07% more ownership
Funds ownership: 28.69% → 30.76% (+2.1%)
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QA
Quantitative Advantage
Minnetonka,
Minnesota
|
+$5.94M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.53M |
| 3 |
Jane Street
New York
|
+$2.41M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.07M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$1.25M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$649K |
| 3 |
NPC
National Planning Corporation
El Segundo,
California
|
-$335K |
| 4 |
Morgan Stanley
New York
|
-$320K |
| 5 |
SAM
SignalPoint Asset Management
Springfield,
Missouri
|
-$227K |
PBE Hedge Fund Activity: Q1 2015 in Review
87 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2015, worth a combined $165M — up 28% from $129M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PBE positions and 8 closed out — a net gain of 6 holders — while 24 added to existing stakes and 22 trimmed.
The largest buyer was Quantitative Advantage, opening a new position worth an estimated $5.94M. The largest seller was Compagnie Lombard Odier SCmA, exiting entirely with an estimated $1.25M sold.
- 87 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2015, up from 82 in Q4 2014.
- Funds reported $165M of Invesco Biotechnology & Genome ETF stock for Q1 2015, up 28% quarter-over-quarter.
- 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2015 and 8 closed out, a net change of +6 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2015 was Quantitative Advantage, an estimated $5.94M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2015 was Compagnie Lombard Odier SCmA, an estimated $1.25M sold.
Based on aggregated 13F filings for Q1 2015.